Company intelligence / Profile preview
Hangzhou Grand Biologic Pharmaceutical Inc.
Hangzhou, Zhejiang Province, Chinahzydsw.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has approved products including a Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus product approved in China on March 2, 2006, for constipation and other indications. They also have products in various clinical stages including IND approval, Phase 1, and Phase 2 stages as of April 2025[2].
- Therapeutic areas
- GastroenterologyImmunologyMetabolic Disorders
- Modalities
- ProbioticsLive biotherapeutic products (LBPs)Enzyme
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
TenNor Therapeutics (for rifasutenizol)CommBio Therapeutics
Beyond the preview
Go deeper on Hangzhou Grand Biologic Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Grand Biologic Pharmaceutical Inc..